Sodium-Glucose Cotransporter-2 Inhibitors for Type 2 Diabetes and Chronic Kidney Disease

This content has been fully sponsored by Boehringer Ingelheim. Boehringer Ingelheim had no influence or involvement over the
content beyond checking for factual accuracy. Editorial and content decisions were made solely by the authors.